Ondansetron Basi

Ondansetron, the active ingredient in Ondansetron Basi, is a 5-HT3 receptor antagonist presented as a strength/form for oral use. It treats nausea and vomiting associated with chemotherapy, radiation therapy, and surgery in adults and children. GNH USA supplies Ondansetron Basi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Ondansetron Basi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron is used to manage nausea and vomiting by targeting the serotonergic pathways involved in emesis.

- Chemotherapy‑induced nausea and vomiting: helps prevent and control acute and delayed episodes. - Radiation‑induced nausea and vomiting: reduces the frequency and severity of symptoms. - Post‑operative nausea and vomiting: decreases the incidence of nausea after surgery. - Hyper‑emesis gravidarum (off‑label): may be considered when conventional therapy fails.

Side effects are generally mild to moderate and vary with the route of administration.

Common Side Effects: - Headache - Constipation - Diarrhea - Fatigue - Dizziness

Serious or Rare Side Effects: - QT interval prolongation - Severe allergic reaction (anaphylaxis) - Serotonin syndrome - Cardiac arrhythmias - Hepatotoxicity

When using Ondansetron Basi, consider the following precautions to ensure safe administration.

- Cardiac monitoring: patients with known QT prolongation or electrolyte disturbances should be monitored. - Electrolyte balance: correct hypokalemia, hypomagnesemia, or hypocalcemia before use. - Concomitant serotonergic drugs: assess risk of serotonin syndrome. - Pregnancy: use only if the potential benefit outweighs the risk. - Breastfeeding: evaluate risk‑to‑infant before continuation. - Store at ambient temperature: keep in original packaging, protect from moisture.

Ondansetron may interact with several medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Amiodarone: may increase risk of QT prolongation. - Certain anti‑arrhythmic drugs (e.g., sotalol) that also prolong QT interval. - Other serotonergic agents (e.g., tramadol, linezolid) that raise serotonin levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole) may raise ondansetron plasma levels. - CYP3A4 inducers (e.g., rifampicin) may reduce ondase ntin efficacy. - Antacids containing aluminum or magnesium may reduce absorption.